Cipla Ltd.

Cipla USA, (Cipla) has launched an authorized generic version of Aloxi in the United States under applicable agreements with Helsinn Healthcare SA, in response to the at-risk launch by Teva.

Helsinn Healthcare SA currently manufactures and markets Aloxi in the United States through its licensee Eisai Inc. and its affiliate Helsinn Therapeutics (US) Inc. Aloxi containing palonosetron hydrochloride injections (Eq. 0.25 mg base/5 ml) is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy and for prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

According to IMS Health, Aloxi brand had US sales of approximately $460 million for the 12-month period ending November 2017. Cipla’s Authorized Generic of Aloxi is available for shipping immediately.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.